Prolonged in vivo anticoagulant activity of a hirudin - Albumin fusion protein secreted from Pichia pastoris

Blood Coagulation and Fibrinolysis

Volumn 12, Issue 6, 2001, Pages 433-443

  Sheffield, William P ^a   Smith, I J ^a   Syed, S ^a   Bhakta, V ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Albumin; Coagulation; Fusion protein; Hirudin; Thrombin

Indexed keywords

ALBUMIN; HIRUDIN; HIRUDIN ALBUMIN FUSION PROTEIN; HYBRID PROTEIN; THROMBIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; DRUG HALF LIFE; IMMUNOGENICITY; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PICHIA PASTORIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN SECRETION; RABBIT; SPECTROMETRY; THROMBIN TIME;

AMINO ACID SEQUENCE; ANIMALS; ANTICOAGULANTS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GENE EXPRESSION; HIRUDINS; HUMANS; PICHIA; RABBITS; RECOMBINANT FUSION PROTEINS; SERUM ALBUMIN; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; THROMBIN; TRANSFECTION;

EID: 0034866996     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200109000-00003     Document Type: Article

References (35)

1. Hirudin: The famous anticoagulant agent
2. Direct thrombin inhibition with rec-hirudin (CGP 39393) as prophylaxis of thromboembolic complications after total hip replacement
3. Heparin-induced thrombocytopenia with thromboembolic complications: Meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range
4. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial
5. Comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes
6. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: A pilot study
7. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infraction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: A randomised trial
8. Design baseline characteristics, and preliminary clinical results of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) trial
9. Direct thrombin inhibitors for treatment of arterial thrombosis: Potential differences between bivalirudin and hirudin
10. Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin
11. On glucose transport and non-enzymic glycation of proteins in vivo
12. The turnover rate of serum albumin in man as measured by I-131-tagged albumin
13. Enzymatic manipulation of DNA and RNA
14. Studies on the transformation of intact yeast cells by the LiAc/SS-DNA/PEG procedure
15. Comparison of the esterase activities of trypsin, plasmin, and thrombin on guanidinobenzoate esters. Titration of the enzymes
16. Determination of specific activity of recombinant hirudin using a thrombin titration method
17. Modulation of clearance of recombinant serum albumin by either glycosylation or truncation
18. Use of kinetic analysis and mathematical modeling in the study of metabolic pathways in vivo
19. Behaviour of radioiodinated rabbit antithrombin III. Demonstration of a non-circulating vascular compartment
20. Comparative evaluation of a partial thromboplastin reagent containing a non-settling, activator
21. A quantitative thrombin time for determining levels of hirudin and Hirulog
22. Anophelin: Kinetics and mechanism of thrombin inhibition
23. Protein and cell membrane iodination with a sparingly soluble chloramide-1,3,4,6-tetrachloro-3,6-diphenylglycoluril
24. Peptide and protein identification by matrix-assisted laser desorption ionization (MALDI) and MALDI-postsource decay time-of-flight mass spectrometry
25. The development of recombinant human serum albumin
26. Interaction of the N-terminal region of hirudin with the active-site cleft of thrombin
27. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial
28. Hirudin in acute coronary syndromes: When cents override good sense
29. Expression of hirudin fusion proteins in mammalian cells: A strategy for prevention of intravascular thrombosis
30. Synthesis and characterization of a recombinant hirudin-albumin complex
31. In vivo assessment of a novel dacron surface with covalently bound recombinant hirudin
32. Fibrin-targeted recombinant hirudin inhibits fibrin deposition on experimental clots more efficiently than recombinant hirudin
33. Construction and functional evaluation of a single-chain antibody fusion protein with fibrin targeting and thrombin inhibition after activation by factor Xa
34. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors
35. Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II